Cleara Biotech B.V., based in Utrecht, the Netherlands, focuses on developing therapeutics aimed at selectively eliminating senescent and senescent-like cancer cells. The company is particularly engaged in creating FOXO4-based anti-senescence drugs designed to counteract chemotoxicity and address therapy-resistant cancer cells. By targeting these problematic cells, Cleara Biotech seeks to advance cancer treatment and improve patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.